Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

BIOHIT Healthcare OY

Offers technologies and services for diagnosing and preventing gastrointestinal diseases and associated risks read more Featured Products: More products

Download Mobile App




Finnish Gastric Cancer Biomarker Tests to Be used in Large Chinese Screening Study

By LabMedica International staff writers
Posted on 11 Aug 2015
A panel of tests produced by a Finnish biomedical company that assess gastric cancer risk will be used in a large screening study of asymptomatic persons in China.

The Biohit Oyj (Helsinki, Finland) GastroPanel is a set of four ELISA kits that diagnose Helicobacter pylori infection and atrophic gastritis by determining levels of the biomarkers pepsinogen I (PGI), pepsinogen II (PGII), gastrin-17 (G-17), and H. More...
pylori antibodies. The tests are noninvasive and performed upon small blood samples.

The gastric cancer risk screening study was organized by the China Health Promotion Foundation, a public organization managed by the Chinese Ministry of Health. Testing of approximately 500,000 40–80-year-old asymptomatic persons with GastroPanel assays will be conducted at fifty to one hundred primary healthcare centers across China. Collection of samples began in the summer of 2015, and data collection and analysis, including evaluation, are planned to be finalized by the end of 2016.

Semi Korpela, CEO of Biohit Oyj, said, "This is an outstanding opening for GastroPanel biomarkers in the screening of asymptomatic subjects to disclose the risk groups for gastric cancer and vitamin B12 malabsorption among other things. Gastric cancer is the leading cause of cancer related mortality in China. The use of the very informative GastroPanel for the screening of gastric cancer risk offers the possibility for the prevention and early detection of stomach cancers. Based on correct diagnosis, screening reduces sick leaves and loss of labor input, as well as self-medication with its associated risks. Early detection of risk conditions for gastric cancer and vitamin and mineral deficiencies saves healthcare costs and human suffering as well."

Related Links:

Biohit Oyj



Gold Member
Immunochromatographic Assay
CRYPTO Cassette
POC Helicobacter Pylori Test Kit
Hepy Urease Test
8-Channel Pipette
SAPPHIRE 20–300 µL
New
Gold Member
Clinical Drug Testing Panel
DOA Urine MultiPlex
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.